$4.38
-0.28-6.01%
Last update: Nov 5, 7:27 PM
Savara Inc (SVRA) Stock Price, Quote, News & History
SVRANASDAQ
Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025.
You can purchase shares of Savara (NASDAQ:SVRA) through any online brokerage.
Other companies in Savara’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Savara has a consensus price target of $8.71.
The stock price for Savara (NASDAQ: SVRA) is $4.32 last updated November 5, 2026 at 7:27 PM EST.
There are no upcoming dividends for Savara.
Savara does not have any upcoming earnings scheduled.
There is no upcoming split for Savara.
Savara is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled...
